Rani Therapeutics Holdings宣布,已与Progen公司合作正式启动Rt-114 Ranipill®用于肥胖症治疗的I期临床研究。该试验旨在评估这款口服制剂的安全性、耐受性及初步疗效,为后续开发奠定基础。
Rani Therapeutics Holdings宣布,已与Progen公司合作正式启动Rt-114 Ranipill®用于肥胖症治疗的I期临床研究。该试验旨在评估这款口服制剂的安全性、耐受性及初步疗效,为后续开发奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.